Boya Bio-Pharmaceutical Group Co.Ltd(300294) goodwill impairment test report
Company code: Boya Bio-Pharmaceutical Group Co.Ltd(300294) company abbreviation: Boya Bio-Pharmaceutical Group Co.Ltd(300294) Boya Bio-Pharmaceutical Group Co.Ltd(300294)
2021 goodwill impairment test report
1、 Whether to conduct impairment test √ yes □ No 2. Whether to obtain the evaluation report for the purpose of financial report in the impairment test √ yes □ no
Asset group name appraisal institution appraiser appraisal report no. appraisal value type appraisal result
Guizhou Tian’an Pharmaceutical Co., Ltd. North Northking Information Technology Co.Ltd(002987) Yashi asset appraisal report of North Yashi
Ltd. (“Tian’an pharmaceutical evaluation office (special Pu Zhang Zheng, Wang Xinhua [2022] No. 01-140) recoverable amount 40778000000
(general partnership)
Nan Jing Xin Jie Kou Department Store Co.Ltd(600682) Pharmaceutical Co., Ltd. North Northking Information Technology Co.Ltd(002987) ASI assets North ASI review Zi
The recoverable amount of appraisal firm (special Pu Zheng, Wang Xinhua) is 66419000000
Company (“Xinbai pharmaceutical”) Tong partnership [2022] No. 01-141
Guangdong Fuda Pharmaceutical Co., Ltd. North Northking Information Technology Co.Ltd(002987) ASI assets North ASI review
The recoverable amount of appraisal firm (special Pu Zheng, Wang Xinhua) is 28907000000
Company (“Fuda pharmaceutical”) Tong partnership [2022] No. 01-142
3、 Are there any signs of impairment
Whether the asset group name has impairment trace remarks whether to withdraw impairment remarks impairment basis remarks
as
There is no sign of impairment in Tian’an pharmaceutical. No, it is not applicable
Xinbai pharmaceutical has no sign of impairment. No, it is not applicable
There is no sign of impairment in Fuda pharmaceutical. No, it is not applicable
4、 Allocation of goodwill
Unit: Yuan
Asset group name asset group or asset group combination asset group or asset group combination asset group or asset group group goodwill allocation method the composition of the original value of goodwill is determined by the carrying amount of the method
In accordance with the relevant provisions of the accounting standards, the main cash generated by the asset group is used to classify the company as a whole
Tian’an pharmaceutical stipulates whether the main inflow of Tian’an pharmaceutical is independent of other assets 34493018751 as the asset group for 22802080380 business operating assets recognition or the cash inflow of the asset group as the impairment test
Is an asset group. basis
In accordance with the relevant provisions of the accounting standards, the main cash generated by the asset group is used to classify the company as a whole
Xinbai pharmaceutical stipulates whether the main inflow of Xinbai pharmaceutical is independent of other assets 59425273074 as the asset group for 37102619946 business operating assets recognition or the cash inflow of the asset group as the impairment test
Basis for an asset group
In accordance with the relevant provisions of the accounting standards, the main cash generated by the asset group is used to classify the company as a whole
According to the regulations of Fuda pharmaceutical, whether the main business inflow of Fuda pharmaceutical is independent of other assets 20436158373 is the asset group for the recognition of business operating assets on 20252211624, or the cash inflow of the asset group is the impairment test
Basis for an asset group
Whether the determination method of asset group or asset group combination is different from that of previous years: □ yes √ no v. goodwill impairment test process 1. Important assumptions and reasons. The group has evaluated the recoverable amount of goodwill of the above subsidiaries. The group takes each subsidiary with goodwill as an asset group for impairment test. The recoverable amount of each subsidiary with goodwill is determined according to the present value of the estimated future cash flow of each subsidiary. The management forecasts the future cash flow according to the detailed forecast period of 5 years and the subsequent forecast period. The estimated future cash flow in the detailed forecast period is determined based on the business plan formulated by the management.
The estimated future cash flow in the subsequent forecast period is determined according to the level of the last year of the detailed forecast period, combined with the group’s business plan, industry development trend, inflation rate and other factors. The group adopts the pre tax discount rate that can reflect the specific risks of relevant asset groups or asset portfolios, which is 12.46% – 14.33%.
Boya Bio-Pharmaceutical Group Co.Ltd(300294) goodwill impairment test report
Based on the business plans of each subsidiary, the Group determines the sales growth rate during the forecast year according to historical experience and market development forecast. The gross profit margin during the forecast year is based on the average gross profit margin achieved in the year before the budget year, which is appropriately determined according to the improvement of expected efficiency and expected market development. 2. Book value of overall asset group or asset group combination
Unit: Yuan
Asset groups belonging to shareholders of the parent company or asset groups belonging to minority shareholders, asset groups containing goodwill, book value of goodwill, book value of goodwill, book value of all goodwill and book value of other assets or combination of asset groups
Guizhou Tian’an Pharmaceutical Co., Ltd
Ltd. (“Tian’an pharmaceutical 1267476440010127315980228020803801169093837134493018751 industry”)
Nan Jing Xin Jie Kou Department Store Co.Ltd(600682) Pharmaceutical Co., Ltd. 37102619946 – 371026199462232265312859425273074 (“Xinbai pharmaceutical”)
Guangdong Fuda Pharmaceutical Co., Ltd. 1660681353236453980922025221162418394674920436158373 company (“Fuda pharmaceutical”) 3. Recoverable amount (1) net amount of fair value minus disposal expenses □ applicable √ not applicable (2) present value of estimated future net cash flow √ applicable □ not applicable
Unit: Yuan
Asset group name forecast period business forecast period profit forecast period net stable period business stable period profit stable period net expected future said forecast period business income profit increase rate profit stable period business income profit increase rate profit discount rate cash net flow long rate long rate present value of long rate quantity
43,909180
Tian’an pharmaceutical May 28% ~ September 20, 2022 2 17.23% ~ 1.33 ~ 2027 ~ 0% 18.77% 6685066212.48% 40778000 – 2026 6 6% 8.77% 66850662 sustainable year. 07 0.00
.07
51,022462
Xinbai Pharmaceutical Co., Ltd. – 4.88% ~ 4.88% in 202210.50% ~ 1.29 ~ 2027 ~ 0% 16.73% 8836765812.46% 66419000 – 202612% 6.73% 88367658 sustainable year.41 0.00
.41
71,484484
Fuda pharmaceutical 7.55% ~ 13.5% in 2022 7.76% ~ 9.4.23 ~ 2027 ~ 0% 7.76% 8179102614.33% 28907000 – 202653% 2% 81791026 sustainable year.34 0.00
.34
yes
Growth rate of operating revenue in 2020 time point forecast period
Whether the growth rate of operating revenue in the forecast period is inconsistent with that in the previous period, Tian’an pharmaceutical: – 6.62% ~ 9.9% 86%
Xinbai pharmaceutical: 5.12% ~ 10.89%
Fuda pharmaceutical: 6.07% ~ 9.15%
